Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Comprehensive clinical development programs being initiated for each investigational candidate
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge and logic
Furthering cell therapy ambition across oncology and autoimmune diseases
US FDA approval based on NEURO-TTRansform Phase III results
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
10+ emerging markets, Japan & ANZ transition in final phase
Subscribe To Our Newsletter & Stay Updated
